Physician profile
Barbara S Terpstra
NPI 1396945184
$732.94
in general payments reported to CMS, 2019-2025
9 companies · $91.62 in 2025
The $91.62 reported for 2025 was less than what a typical Phlebology provider received nationally (typical 2025 total: $141).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.19 · 2020: $99.79 · 2021: $155 · 2022: $47.40 · 2023: $16.08 · 2024: $300 · 2025: $91.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $407.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Koya Medical, INC. | $331.22 | 2024-2025 | Dayspring, Koya Medical, Dayspring |
| Tactile Systems Technology INC | $142.71 | 2020-2023 | Entre Plus, Flexitouch Plus |
| Boston Scientific Corporation | $63.87 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $61.54 | 2022-2025 | Eliquis |
| Organogenesis INC. | $37.65 | 2021 | |
| Angiodynamics, INC. | $26.81 | 2021 | |
| Medtronic, INC. | $26.50 | 2022 | |
| Biocompatibles, INC. | $23.19 | 2019 | |
| Cashflow Solutions, LLC | $19.45 | 2025 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Terpstra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.